ImmunityBio Reports Sevenfold Revenue Surge Driven by Global Expansion

ImmunityBio reports $113M in 2025 Anktiva sales, a 700% surge. The drug gains EU approval for bladder cancer and a new lung cancer indication in Saudi Arabia.

ImmunityBio has announced remarkable financial results for 2025, headlined by a dramatic increase in revenue for its immunotherapy drug, Anktiva. Sales soared to approximately $113 million, representing a staggering 700 percent year-over-year gain. This financial acceleration coincides with a rapid global commercialization push, with the biotech firm securing regulatory approvals in 33 countries.

International Footprint Broadens Rapidly

A cornerstone of the company's strategy is geographic expansion, achieved at a notable pace. ImmunityBio has established its international presence in under two years since Anktiva received U.S. Food and Drug Administration (FDA) approval in April 2024. Existing approvals in the United States, United Kingdom, and Saudi Arabia were recently joined by a significant regulatory milestone in Europe.

The European Commission granted conditional marketing authorization for Anktiva. The approval covers its use, in combination with BCG, for a specific type of non-muscle invasive bladder cancer across all 27 European Union member states, as well as Iceland, Norway, and Liechtenstein. This opens a substantial new market for the therapy.

Momentum Builds Through Year-End

The company's growth trajectory showed further strengthening as the year progressed. During the fourth quarter of 2025, revenue increased by 20 percent compared to the preceding quarter, indicating that the commercial rollout for Anktiva is gathering significant momentum.

New Therapeutic Indication Approved

Beyond bladder cancer, ImmunityBio has secured its first approval for a second disease area. In January 2026, the Saudi Food and Drug Authority (SFDA) authorized Anktiva for a new indication: treating metastatic non-small cell lung cancer in combination with checkpoint inhibitors. This makes Saudi Arabia the first country worldwide to clear the drug for this application, marking a pivotal step in broadening its clinical utility.

Strategic Alliances Facilitate Global Rollout

To support its commercial execution, ImmunityBio has formed key partnerships. The launch in Europe is being conducted in collaboration with Accord Healthcare, supported by a newly established Irish subsidiary. For the Middle East and North Africa region, the company is working with distribution partners Biopharma and Cigalah Healthcare. In Saudi Arabia, Anktiva is slated to become available within 60 days of the January announcement regarding the new lung cancer indication.

The convergence of robust revenue growth, strategic geographic expansion, and progress into new treatment areas signals an accelerating commercialization phase for ImmunityBio. Forthcoming quarterly reports will reveal if this positive momentum can be sustained.